Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Cancer Pharmacogenomics and Targeted Therapies
Document related concepts
no text concepts found
Transcript
Cancer Pharmacogenomics and Targeted Therapies 15-17 September 2013 Wellcome Trust Conference Centre, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK The development of new cancer therapies is increasingly guided by our understanding of the molecular basis of cancer. As worldwide efforts are beginning to provide a comprehensive description of the genomic, transcriptomic and epigenomic changes that occur in cancer, the field of cancer pharmacogenomics will be at the forefront of a new generation of rationally designed cancer therapies incorporating molecular biomarkers. These hold the promise of improved clinical responses by enabling the stratification of patients most likely to benefit from a specific treatment. This conference is aimed at scientists and clinician-scientists in academia or industry and will seek to address many of the key challenges in the design, development and clinical implementation of targeted cancer therapies. Scientific topics will include: • Cancer Genomics • Drugging the Cancer Genome • Experimental and pre-clinical therapeutic models • Combating drug resistance • Molecular biomarkers in the clinic Scientific Organisers Rene Bernards The Netherlands Cancer Institute Mathew Garnett Wellcome Trust Sanger Institute, UK Ultan McDermott Wellcome Trust Sanger Institute, UK Mike Stratton Wellcome Trust Sanger Institute, UK Dave Tuveson Cold Spring Harbor Laboratory, USA Confirmed speakers include: Bissan Al-Lazikani Institute for Cancer Research, London, UK Alberto Bardelli Institute for Cancer Research and Treatment at Candiolo, Italy Lynda Chin MD Anderson Cancer Centre, USA Johann de Bono Institute for Cancer Research, London, UK Julian Downward Cancer Research UK London Research Institute Mikala Egeblad Cold Spring Harbour Laboratories, USA Jeff Engelman Massachusetts General Hospital Cancer Center, USA Manel Esteller Cancer Epigenetics and Biology Program, Spain Keith Flaherty Massachusetts General Hospital, USA Levi Garraway Dana Faber Cancer Institute, USA Stefan Pfister German Cancer Research Center David Rees Astex Pharmaceuticals, USA David B. Solit Memorial Sloan-Kettering Cancer Center, USA Robert Vries Hubrecht Institute, The Netherlands Lodewyk Wessels TheNetherlands Cancer Institute Paul Workman Institute for Cancer Research, London, UK Registration & Abstract Deadline: 28 June 2013 Full details can be found at https://registration.hinxton.wellcome.ac.uk/display_info.asp?id=348
